| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $47,474 | 5 | 100 |
| Albertson Tina M. | Chief Medical Officer | 0 | $0 | 1 | $2,089 | $-2,089 |
| Khan Ruhi Ahmad | Chief Business Officer | 0 | $0 | 1 | $13,598 | $-13,598 |
| MCCLUNG BARBARA G | Chief Legal Officer | 0 | $0 | 1 | $13,598 | $-13,598 |
| Kelly Timothy P | Chief Technology Officer | 0 | $0 | 2 | $18,188 | $-18,188 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Over the last 12 months, insiders at Caribou Biosciences, Inc. have bought $0 and sold $47,474 worth of Caribou Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Caribou Biosciences, Inc. have bought $172,197 and sold $230,198 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $20,400 was made by Haurwitz Rachel E. (President and CEO) on 2025‑03‑14.
| 2026-02-25 | Sale | Kelly Timothy P | Chief Technology Officer | 6,228 0.0066% | $1.93 | $12,020 | +1.03% | |
| 2026-02-24 | Sale | MCCLUNG BARBARA G | Chief Legal Officer | 6,938 0.0068% | $1.96 | $13,598 | -7.94% | |
| 2026-02-24 | Sale | Khan Ruhi Ahmad | Chief Business Officer | 6,938 0.0068% | $1.96 | $13,598 | -7.94% | |
| 2026-02-24 | Sale | Kelly Timothy P | Chief Technology Officer | 3,147 0.0031% | $1.96 | $6,168 | -7.94% | |
| 2026-02-24 | Sale | Albertson Tina M. | Chief Medical Officer | 1,066 0.001% | $1.96 | $2,089 | -7.94% | |
| 2025-03-14 | Haurwitz Rachel E. | President and CEO | 20,000 0.0217% | $1.02 | $20,400 | +70.30% | ||
| 2025-02-21 | Sale | MCCLUNG BARBARA G | Chief Legal Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-02-21 | Sale | Kanner Steven | Chief Scientific Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-02-21 | Sale | Khan Ruhi Ahmad | Chief Business Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-01-29 | Ryali Sriram | Chief Financial Officer | 17,360 0.0194% | $1.42 | $24,651 | +20.15% | ||
| 2023-01-19 | Sale | Rizvi Syed Ali-aamir | Chief Medical Officer | 5,627 0.0093% | $6.31 | $35,506 | -15.90% | |
| 2022-10-06 | Sale | Fischesser Ryan | VP of Finance and Controller | 10,000 0.0162% | $10.80 | $107,958 | -43.13% | |
| 2022-08-25 | Sale | Kanner Steven | Chief Scientific Officer | 43,248 0.0707% | $11.22 | $485,221 | -40.99% | |
| 2022-01-11 | Fischesser Ryan | VP of Finance and Controller | 7,387 0.0038% | $4.00 | $29,553 | -29.34% | ||
| 2021-12-20 | Fischesser Ryan | VP of Finance and Controller | 1,136 0.0003% | $2.69 | $3,056 | -38.62% | ||
| 2021-12-07 | MCCLUNG BARBARA G | Chief Legal Officer | 6,127 0.0015% | $2.69 | $16,482 | -50.11% | ||
| 2021-10-20 | MCCLUNG BARBARA G | Chief Legal Officer | 9,219 0.0021% | $2.69 | $24,799 | -50.25% | ||
| 2021-10-12 | Kanner Steven | Chief Scientific Officer | 114,860 0.0179% | $1.92 | $220,757 | -51.66% | ||
| 2021-10-11 | Fischesser Ryan | VP of Finance and Controller | 1,746 0.0004% | $2.69 | $4,697 | -48.53% |
| MCCLUNG BARBARA G | Chief Legal Officer | 481564 0.4855% | $924,602.88 | 2 | 2 | <0.0001% |
| Khan Ruhi Ahmad | Chief Business Officer | 104998 0.1059% | $201,596.16 | 0 | 2 | |
| Kelly Timothy P | Chief Technology Officer | 73125 0.0737% | $140,400.00 | 0 | 2 | |
| Albertson Tina M. | Chief Medical Officer | 68523 0.0691% | $131,564.16 | 0 | 1 | |
| Haurwitz Rachel E. | President and CEO | 3369395 3.3972% | $6.47M | 1 | 0 | +70.3% |
| Kanner Steven | Chief Scientific Officer | 431556 0.4351% | $828,587.52 | 1 | 2 | <0.0001% |
| Fischesser Ryan | VP of Finance and Controller | 110366 0.1113% | $211,902.72 | 3 | 1 | <0.0001% |
| Rizvi Syed Ali-aamir | Chief Medical Officer | 59373 0.0599% | $113,996.16 | 0 | 1 | |
| Ryali Sriram | Chief Financial Officer | 17360 0.0175% | $33,331.20 | 1 | 0 | +20.15% |
$168,352,523 | 35 | 13.58% | $216.91M | |
$16,153,236 | 20 | -28.79% | $171.59M | |
$20,234,041 | 17 | 2.09% | $205.78M | |
$448,999,793 | 15 | -19.99% | $179.58M | |
$156,530,514 | 13 | 45.71% | $207.23M | |
$1,037,470 | 13 | 78.00% | $207.49M | |
$15,799,576 | 12 | -39.52% | $204.43M | |
$19,167,169 | 10 | 28.48% | $199.67M | |
Caribou Biosciences, Inc. (CRBU) | $344,394 | 8 | -22.26% | $190.43M |
$145,296,407 | 8 | -0.98% | $201.2M | |
$2,762,881 | 8 | -10.76% | $215.21M | |
$22,090,972 | 7 | -3.49% | $163.28M | |
$164,999,952 | 5 | -44.44% | $169.31M | |
$32,007,657 | 4 | -45.65% | $184.39M | |
$193,101 | 3 | -25.20% | $207.71M | |
$16,003,671 | 3 | 55.38% | $177.49M | |
$32,289,200 | 3 | -5.46% | $181.53M | |
$12,498 | 2 | 39.61% | $184.53M | |
$86,200 | 1 | -19.57% | $176.46M |
| Increased Positions | 51 | +36.69% | 6M | +19.72% |
| Decreased Positions | 52 | -37.41% | 7M | -20.15% |
| New Positions | 23 | New | 1M | New |
| Sold Out Positions | 13 | Sold Out | 2M | Sold Out |
| Total Postitions | 138 | -0.72% | 33M | -0.43% |
| Vanguard Group Inc | $6,721.00 | 4.55% | 4.23M | +137,060 | +3.35% | 2025-09-30 |
| Millennium Management Llc | $5,114.00 | 3.46% | 3.22M | +2M | +107.44% | 2025-09-30 |
| Kynam Capital Management, Lp | $4,878.00 | 3.3% | 3.07M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $2,320.00 | 1.57% | 1.46M | -424,156 | -22.52% | 2025-09-30 |
| Aberdeen Group Plc | $2,208.00 | 1.49% | 1.39M | +491,326 | +54.74% | 2025-09-30 |
| Pfm Health Sciences, Lp | $2,161.00 | 1.46% | 1.36M | 0 | 0% | 2025-09-30 |
| Two Sigma Advisers, Lp | $1,952.00 | 1.32% | 1.23M | -220,400 | -15.22% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $1,924.00 | 1.3% | 1.21M | -97,045 | -7.42% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,708.00 | 1.16% | 1.07M | +265,542 | +32.83% | 2025-09-30 |
| Geode Capital Management, Llc | $1,566.00 | 1.06% | 985,126 | +4,197 | +0.43% | 2025-09-30 |